全文获取类型
收费全文 | 30687篇 |
免费 | 2168篇 |
国内免费 | 645篇 |
专业分类
耳鼻咽喉 | 618篇 |
儿科学 | 3408篇 |
妇产科学 | 152篇 |
基础医学 | 5738篇 |
口腔科学 | 185篇 |
临床医学 | 2666篇 |
内科学 | 5670篇 |
皮肤病学 | 138篇 |
神经病学 | 724篇 |
特种医学 | 644篇 |
外科学 | 2569篇 |
综合类 | 4050篇 |
现状与发展 | 3篇 |
预防医学 | 1862篇 |
眼科学 | 109篇 |
药学 | 2895篇 |
30篇 | |
中国医学 | 1609篇 |
肿瘤学 | 430篇 |
出版年
2023年 | 503篇 |
2022年 | 874篇 |
2021年 | 1381篇 |
2020年 | 1187篇 |
2019年 | 1382篇 |
2018年 | 1323篇 |
2017年 | 1128篇 |
2016年 | 1147篇 |
2015年 | 1123篇 |
2014年 | 2056篇 |
2013年 | 3056篇 |
2012年 | 1704篇 |
2011年 | 1827篇 |
2010年 | 1337篇 |
2009年 | 1363篇 |
2008年 | 1374篇 |
2007年 | 1419篇 |
2006年 | 1299篇 |
2005年 | 1058篇 |
2004年 | 825篇 |
2003年 | 685篇 |
2002年 | 613篇 |
2001年 | 584篇 |
2000年 | 472篇 |
1999年 | 448篇 |
1998年 | 366篇 |
1997年 | 375篇 |
1996年 | 293篇 |
1995年 | 184篇 |
1994年 | 195篇 |
1993年 | 144篇 |
1992年 | 124篇 |
1991年 | 121篇 |
1990年 | 129篇 |
1989年 | 89篇 |
1988年 | 89篇 |
1987年 | 76篇 |
1986年 | 90篇 |
1985年 | 147篇 |
1984年 | 110篇 |
1983年 | 87篇 |
1982年 | 105篇 |
1981年 | 92篇 |
1980年 | 96篇 |
1979年 | 74篇 |
1978年 | 55篇 |
1977年 | 42篇 |
1976年 | 70篇 |
1974年 | 48篇 |
1973年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Archivos de bronconeumología》2022,58(1):11-21
BackgroundWe aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment.MethodsMulticentre retrospective observational cohort study in COPD patients who had received ≥1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication.ResultsOf 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ≥three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%).ConclusionsIn COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis. 相似文献
2.
3.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
4.
5.
6.
7.
《Journal of vascular and interventional radiology : JVIR》2020,31(7):1103-1109
PurposeTo explore the safety and effectiveness of bronchial artery (BA) embolization (BAE) in children with pulmonary hemorrhage.Materials and MethodsBetween February 2016 and February 2019, 41 patients (median age, 4 y; interquartile range, 2.3-8 y; median weight, 17.6 kg; interquartile range, 12.3–23.6 kg) underwent BAE. The indication of BAE included massive hemoptysis in 10 patients (24.4%), recurrent hemoptysis in 18 patients (43.9%), and refractory anemia in 13 patients (31.7%). The main etiology of pulmonary hemorrhage included pulmonary hemosiderosis (58.5%), congenital heart disease (17.1%), and infection (14.6%). A retrospective review was conducted of clinical outcomes of BAE.ResultsThere were 44 embolization sessions, with a total of 137 embolized vessels. Pulmonary hemorrhage was caused by BAs in 30 cases, nonbronchial systemic arteries plus BAs in 10, and nonbronchial systemic arteries in 1. Embolic particles were used in 30 cases (24 polyvinyl alcohol [PVA] and 6 microsphere), coils in 9 cases, and particles plus coils in 5 cases (4 PVA and 1 microsphere). Technical success (ability to embolize abnormal vessel) was achieved in 97.6% of patients (40 of 41), and clinical success (complete or partial resolution of hemoptysis within 30 days of embolization) was achieved in 90.2% (37 of 41). There was 1 procedure-related complication (2.4%) of cerebral infarction and 1 death from multiple-organ dysfunction (2.4%). Bleeding-free survival rates at 6, 12, 24, and 36 months were 92.5%, 83.9%, 83.9%, and 70.8%, respectively.ConclusionsBAE is a safe and effective procedure in children with pulmonary hemorrhage. 相似文献
8.
9.
10.